A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs

New England Journal of Medicine

Volumn 338, Issue 11, 1998, Pages 719-726

  Yeomans, Neville D ^a   Tulassay, Zsolt ^b   Juhász, László ^c   Rácz, István ^d   Howard, John M ^e   Van Rensburg, Christoffel J ^f   Swannell, Anthony J ^g   Hawkey, Christopher J ^h  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c Borsod County Teaching Hospital   (Hungary)

^d Endocrinology and Diabetology   (Hungary)

^e Division of Gastroenterology   (Canada)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PREDNISOLONE; RANITIDINE; UREASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENUM ULCER; ENDOSCOPY; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; STOMACH EROSION; STOMACH ULCER; ULCER HEALING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DUODENAL ULCER; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROGNOSIS; PROTON PUMPS; RANITIDINE; REMISSION INDUCTION; STOMACH ULCER;

EID: 0032510315     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803123381104     Document Type: Article

References (35)

1. Paakkari H. Epidemiological and financial aspects of the use of non-steroidal anti-inflammatory analgesics. Pharmacol Toxicol 1994;75:Suppl 2:56-9.
2. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
3. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl 1989;163:3-8.
4. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986;1:489-92.
5. Ivey KJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage: actions of therapeutic agents. Am J Med 1988;84:Suppl 2A:41-8.
6. Hogben CAM, Schanker LS, Tocco DJ, Brodie BB. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957;120:540-5.
7. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996;23:432-4.
8. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252-5.
9. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
10. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-8.
11. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
12. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1990;31:514-7.
13. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39:97-103.
14. Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989;320:69-75.
15. Lauritsen K, Rutgersson K, Boiling E, et al. Omeprazole 20 or 40 mg daily for healing of duodenal ulcer? A double-blind comparative study. Eur J Gastroenterol Hepatol 1992;4:995-1000.
16. EEC note for guidance: good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol 1990;67:361-72.
17. Cullen DJ, Hawkey GM, Humphries H, et al. Role of non-steroidal anti-inflammatory drugs and Helicobacter pylori in bleeding peptic ulcer. Gastroenterology 1994;106:Suppl:A66. abstract.
18. Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997;41:459-62.
19. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748-51.
20. Soil AH. Medical treatment of peptic ulcer disease: practice guidelines: Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996;275:622-9.
21. Langman MJ, Brooks P, Hawkey CJ, Silverstein F, Yeomans ND. Non-steroidal anti-inflammatory drug associated ulcer: epidemiology, causation and treatment. J Gastroenterol Hepatol 1991;6:442-9.
22. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817-22.
23. Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 1996;31;753-8.
24. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal pro phylaxis with omeprazole for NSAID users. Aliment Pharmacol Ther (in press).
25. Roth SH, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy: double-blind long-term evaluation. Arch Intern Med 1987;147:1798-801.
26. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
27. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol 1994;23:171-6.
28. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.
29. Taha AS, Capell HA, Sturrock RD, Russell RI. Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs. Am J Gastroenterol 1991;86:1588-91.
30. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gas trointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
31. Dajani EZ, Agrawal NM. Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs. Dig Dis 1995;13:Suppl 1:48-61.
32. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987;28:1120-7
33. Reynolds JC. Famotidine therapy for active duodenal ulcers: a multivariate analysis of factors affecting early healing. Ann Intern Med 1989;111:7-14.
34. Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991;100:1653-7.
35. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.